logo-loader
viewSareum Holdings PLC

Sareum Holdings new licensing deal 'could generate significant near-term milestone revenue'

Sareum Holdings PLC's (LON:SAR) Tim Mitchell speaks to Proactive's Andrew Scott soon after announcing a licensing deal with an unnamed Chinese specialty pharmaceutical company.

The firm will develop Sareum's FLT3+Aurora kinases portfolio, including SAR-20293, a preclinical drug candidate for acute myeloid leukaemia and other blood-borne cancers.

Quick facts: Sareum Holdings PLC

Price: 0.71 GBX

AIM:SAR
Market: AIM
Market Cap: £21.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: IQ-AI rockets as it receives StoneChecker FDA clearance

Headlines from the Proactive UK newsroom. IQ-AI (LON:IQAI) has received FDA clearance to market its StoneChecker Software in the US. IQ-AI said it was delighted with the decision. Synairgen (LON:SNG) is to present biomarker data from the first part of its ongoing Phase II trial of its...

on 27/9/19

2 min read